Predictors of Outcome following Stroke due to Isolated M2 Occlusions

Muhib Khan\textsuperscript{a} Richard P. Goddeau Jr.\textsuperscript{b} Jayne Zhang\textsuperscript{b} Majaz Moonis\textsuperscript{b} Nils Henninger\textsuperscript{b, c}

\textsuperscript{a}Department of Neurology, Warren Alpert Medical School of Brown University, Providence, R.I., and Departments of \textsuperscript{b}Neurology and \textsuperscript{c}Psychiatry, University of Massachusetts Medical School, Worcester, Mass., USA

**Key Words**
M2 occlusion · Outcome · Cortical infarct · Stroke · Thrombolysis

**Abstract**

**Background:** Factors influencing outcome after cerebral artery occlusion are not completely understood. Although it is well accepted that the site of arterial occlusion critically influences outcome, the majority of studies investigating this issue has focused on proximal large artery occlusion. To gain a better understanding of factors influencing outcome after distal large artery occlusion, we sought to assess predictors of outcome following isolated M2 middle cerebral artery occlusion infarcts. **Methods:** We retrospectively analyzed patients with isolated acute M2 occlusion admitted to a single academic center from January 2010 to August 2012. Baseline clinical, laboratory imaging, and outcome data were assessed from a prospectively collected database. Factors associated with a modified Rankin Scale (mRS) score \(\leq 2\) in univariable analyses (\(p < 0.05\)) were entered into multivariable logistic regression analysis. The Admission National Institutes of Health Stroke Scale (aNIHSS) score, age, and infarct volume were also entered as dichotomized variables. Receiver operating characteristic curves were plotted to determine the optimal aNIHSS score, infarct volume, and age cut points predicting an mRS score \(\leq 2\). Optimal thresholds were determined by maximizing the Youden index. Respectively multivariable logistic regression analyses were used to identify independent predictors of a good 90-day outcome (mRS score \(\leq 2\); primary analysis) as well as 90-day mortality (secondary outcome). **Results:** 90 patients with isolated M2 occlusion were included in the final analyses. Of these, 69% had a good 90-day outcome which was associated with age \(<80\)
years (p = 0.007), aNIHSS <10 (p = 0.002), and infarct volume ≤26 ml (p < 0.001). Notably, 20% of patients (64% of those with a poor outcome) had died by 90 days. Secondary analysis for 90-day mortality was performed. This analysis indicated that infarct volume >28 ml (OR 11.874, 95% CI 2.630–53.604, p = 0.001), age >80 years (OR 4.953, 95% CI 1.087–22.563, p = 0.039), need for intubation (OR 7.788, 95% CI 1.072–56.604), and history of congestive heart failure (OR 5.819, 95% CI 1.140–29.695) were independent predictors of 90-day mortality (20% of all included patients).

Conclusion: While the majority of patients with isolated M2 occlusion stroke has a good 90-day outcome, a substantial proportion of subjects dies by 90 days, as identified by a unique subset of predictors. The knowledge gained from our study may lead to an improvement in the prognostic accuracy, clinical management, and resource utilization in this patient population.

Introduction

Acute stroke treatment has evolved significantly over the last two decades, which is in part due to an improved understanding of factors that determine outcome [1]. It is now well understood that the site of arterial occlusion critically influences outcome following acute anterior circulation ischemic stroke [2, 3]. However, the majority of studies investigating this issue has focused on proximal large artery occlusion involving the internal carotid artery (ICA) and proximal middle cerebral artery (MCA) as these represent a particular challenge for medical management [2–4]. For example, recanalization following intervention in ICA and proximal MCA occlusion has been reported to be generally poor [2–4], and has been associated with larger infarct volumes and rarely with good functional outcomes (<40%) even in affected patients with aggressive interventions [2–6]. Conversely, distal MCA occlusions have been associated with higher rates of recanalization following intervention, smaller infarct volumes, and a favorable outcome in the majority of patients (>50%) [2–4]. Yet, the number of investigated patients in these studies was relatively small (n ≤ 100) and most (>80%) were subjected to intravenous (i.v.) or endovascular recanalization approaches. Hence, there remains a paucity of information regarding factors modulating outcome following isolated distal MCA occlusion.

Therefore, we sought to investigate predictors of 90-day functional outcome in patients with infarction due to isolated M2 segment occlusion. Specifically, we assessed for factors associated with a good versus poor 90-day outcome (primary outcome) as well as 90-mortality (secondary outcome).

Methods

Study Population

This study was a retrospective analysis of our prospective database including consecutive acute ischemic stroke patients admitted to a single academic center from January 2010 to August 2012. Only patients with isolated M2 occlusion on computed tomography angiography (CTA) performed at admission were included.

All patients underwent head CT or brain magnetic resonance imaging (MRI) within 7 days after ischemic stroke. Patient demographics, comorbidities, preadmission medications, laboratory data, intubation, requirement for admission at the intensive care unit (ICU), length of hospital stay (LOS), treatment modality [conservative management vs. acute intervention (i.v. thrombolysis and endovascular recanalization)], and stroke etiology [according to the
Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification [7] after completion of diagnostic evaluation were collected in all patients. Admission National Institutes of Health Stroke Scale (aNIHSS) and modified Rankin Scale (mRS) scores were assessed at the time of presentation and at 90 days by a stroke-trained physician or study nurse certified in mRS [8]. This study was reviewed and approved by our Institutional Review Board.

Image Review and Analysis

CT, CTA, and diffusion-weighted imaging were reviewed independently by study physicians masked to clinical data, follow-up scans, patient variables, and outcomes. Details of the used imaging protocols have been previously described [9]. The MCA-M2 segment was defined as the segment extending from the bifurcation/trifurcation of the MCA to the top of the Sylvian fissure to further division [10]. The M2 portion was conceptually further divided into three segments of equal length: proximal, middle, and distal. The ischemic lesion volume was measured manually on follow-up imaging. Hemorrhagic transformation was defined according to the European Cooperative Acute Stroke Study II (ECASS II) criteria [11]. For analysis, hemorrhagic transformation was dichotomized into parenchymal hemorrhage (PH) versus non-PH.

Statistics

Continuous variables are reported as mean ± SD or as median ± interquartile range (IQR). Categorical variables are reported as proportions. The primary analysis was performed to determine factors associated with a good 90-day outcome (mRS 0–2). In light of significant mortality, we further sought to investigate for factors that were independently associated with 90-day mortality in a secondary analysis. Receiver operating characteristic (ROC) curves were plotted to determine the optimal cut point for continuous variables (aNIHSS, age, and infarct volume) predicting a good 90-day outcome and mortality, respectively.

Between-group comparisons for continuous variables were made with unpaired t test, Mann-Whitney U test, and Kruskal Wallis with post hoc Dunn’s method. Categorical variables were compared using the χ² test or Fisher exact test as appropriate. Variables significantly associated with 90-day outcome in the univariable analysis (p < 0.05) were included in the multivariable logistic regression model with backward elimination (likelihood ratio) to identify independent predictors for a good 90-day outcome or 90-day mortality, respectively.

Two-sided significance tests were used throughout and p < 0.05 was considered statistically significant. All statistical analyses were performed using IBM® SPSS® Statistics 20.0.0 (IBM®, Armonk, N.Y., USA).

Results

During the study period, 1,269 patients were admitted for acute ischemic stroke. Of these, 202 patients had an MCA occlusion confirmed by imaging and 106 of them had an occlusion distal to the bifurcation. Sixteen patients with an M3 occlusion were excluded. Thus, 90 patients with isolated M2 occlusions were included for analysis (fig. 1).

Primary Analysis

The majority of patients (69%) had a good 90-day outcome (fig. 2). Baseline characteristics of the included patients as stratified by good (mRS score ≤2) versus poor (mRS score >2) outcome are summarized in table 1. In univariable analysis (table 1), factors associated with a poor 90-day outcome were older age (p = 0.014), a higher aNIHSS (p < 0.001), admission at the intensive care unit (p = 0.002), intubation (p = 0.001), LOS (p = 0.003), presence of
proximal M2 occlusion (p = 0.024), greater infarct volume (p < 0.001), presence of both cortical and subcortical infarcts (p = 0.004), and PH-type conversion (p = 0.036). ROC curve analyses indicated that an aNIHSS ≤10 (sensitivity = 0.836, specificity = 0.931, AUC = 0.917, p < 0.001), age ≤80 years (sensitivity = 0.721, specificity = 0.690, AUC = 0.673, p = 0.008), and infarct volume ≤26 ml (sensitivity = 0.902, specificity = 0.862, AUC = 0.925, p < 0.001) best predicted a good 90-day outcome.

Multivariable logistic regression analysis indicated that age ≤80 years (OR 0.045, 95% CI 0.005–0.435, p = 0.007), aNIHSS ≤10 (OR 0.073, 95% CI 0.014–0.387, p = 0.002), and infarct volume ≤26 ml (OR 0.018, 95% CI 0.002–0.166, p < 0.001) were significant predictors of good 90-day outcome (mRS score 0–2) (table 2). When aNIHSS, age, and infarct volume were entered as continuous variables, multivariable analysis showed that a lower aNIHSS and smaller infarct volume (p = 0.001) were independently associated with a good 90-day outcome (online suppl. table 1; for all online suppl. material, see www.karger.com/doi/10.1159/000360075).

Secondary Analysis
In contrast to the overall good outcome in our patient cohort, a significant proportion of patients with a poor outcome (64%) had died by 90 days. In secondary analyses, we sought
Table 1. Baseline characteristics (unadjusted) of the studied patient population as stratified by good 90-day outcome (mRS score 0–2)

| Characteristics                                      | All patients (n = 90) | Good outcome (mRS 0–2; n = 61) | Poor outcome (mRS 3–6; n = 29) | p value  |
|------------------------------------------------------|-----------------------|--------------------------------|--------------------------------|----------|
| Age, years                                           | 73±15                 | 70±16                          | 78±13                          | 0.014    |
| Female sex                                           | 50 (55.6)             | 31 (50.8)                      | 19 (65.5)                      | n.s.     |
| Median aNIHSS (IQR)                                  | 8 (4–16)              | 6.8 (4–8)                      | 18 (12–24)                     | <0.001   |
| Final TOAST stroke mechanisms                        | n.s.                  |                                 |                                |          |
| Large artery atherosclerosis                          | 8 (9)                 | 7 (11.5)                       | 1 (3.4)                        |          |
| Cardioembolic stroke                                 | 49 (54)               | 31 (51)                        | 18 (62)                        |          |
| Stroke of other/undetermined cause                   | 32 (36)               | 22 (36)                        | 10 (34.5)                      |          |
| Acute intervention                                   | n.s.                  |                                 |                                |          |
| Conservative management                              | 67 (74)               | 45 (74)                        | 22 (76)                        |          |
| i.v. rtPA                                            | 23 (26)               | 16 (26)                        | 7 (24)                         |          |
| Endovascular intervention*                           | 5 (5.6)               | 5 (8.2)                        | 0 (0)                          |          |
| Imaging data                                         |                       |                                |                                |          |
| Final infarct volume, ml                             | 28±32                 | 12.5±14.7                      | 60.4±35                        | <0.001   |
| PH type conversion                                   | 5 (5.6)               | 1 (1.6)                        | 4 (14)                         | 0.036    |
| Proximal M2 occlusion                                | 37 (41)               | 20 (33)                        | 17 (59)                        | 0.024    |
| Cortical plus subcortical infarction                 | 11 (12)               | 3 (5)                          | 8 (28)                         | 0.004    |
| Serum markers                                        |                       |                                |                                |          |
| HbA1c                                                | 6.3±1.1               | 6.4±1.1                        | 6.3±1.2                        | n.s.     |
| Glucose at admission, mg/dl                          | 140±55                | 140±57                         | 141±50                         | n.s.     |
| Creatinine at admission, mg/dl                       | 1.06±0.51             | 1.1±0.37                       | 1.14±0.69                      | n.s.     |
| White blood cells at admission, ×10^3/μl             | 8.6±2.7               | 8.4±2.9                        | 9.3±2.2                        | n.s.     |
| LDL-C, mg/dl                                         | 93±38                 | 97±39                          | 85±36                          | n.s.     |
| HDL-C, mg/dl                                         | 46±15                 | 45±14                          | 48±16                          | n.s.     |
| Preadmission medications                             |                       |                                |                                |          |
| Antiplatelets                                        | 40 (44)               | 30 (49)                        | 10 (34)                        | n.s.     |
| Oral anticoagulation                                 | 9 (10)                | 6 (10)                         | 3 (10)                         | n.s.     |
| Statin                                               | 30 (33)               | 20 (33)                        | 10 (34)                        | n.s.     |
| Antiglycemic                                         | 19 (21)               | 15 (250)                       | 4 (14)                         | n.s.     |
| Antihypertensive                                     | 57 (63)               | 38 (62)                        | 19 (66)                        | n.s.     |
| Preexisting risk factors                             |                       |                                |                                |          |
| Hypertension                                         | 71 (79)               | 47 (77)                        | 24 (83)                        | n.s.     |
| Dyslipidemia                                         | 51 (56)               | 37 (60)                        | 14 (48)                        | n.s.     |
| Diabetes                                             | 31 (34)               | 24 (39)                        | 7 (24)                         | n.s.     |
| Prior stroke or transient ischemic attack            | 13 (14)               | 8 (13)                         | 5 (17)                         | n.s.     |
| Atrial fibrillation                                  | 28 (31)               | 17 (28)                        | 11 (38)                        | n.s.     |
| Coronary artery disease                              | 27 (30)               | 17 (28)                        | 10 (34)                        | n.s.     |
| Congestive heart failure                             | 18 (20)               | 9 (15)                         | 9 (31)                         | n.s.     |
| Renal failure                                        | 2 (2)                 | 1 (2)                          | 1 (3)                          | n.s.     |
| Cancer                                               | 7 (8)                 | 5 (8)                          | 2 (7)                          | n.s.     |
| Peripheral vascular disease                          | 6 (7)                 | 6 (10)                         | 0 (0)                          | n.s.     |
| Current smoking                                      | 22 (24)               | 18 (29)                        | 4 (14)                         | n.s.     |
| Alcohol abuse                                        | 7 (8)                 | 5 (8.2)                        | 2 (7)                          | n.s.     |
| Admission at ICU                                      | 61 (68)               | 35 (58)                        | 26 (90)                        | 0.002    |
| Intubation                                           | 12 (13)               | 3 (5)                          | 9 (31)                         | 0.001    |
| Length of stay, days                                 | 4 (2–6)               | 3 (2–5)                        | 6 (3–11)                       | 0.003    |

Data are n (%) or mean ± SD, except otherwise indicated. * With or without i.v. rtPA.
to investigate for potential unique predictors of mortality. Baseline characteristics of patients as stratified by mortality are shown in online supplementary table 2. Older age (p = 0.011), congestive heart failure (CHF) (p = 0.007), higher aNIHSS (p < 0.001), ICU admission (p = 0.009), intubation (p = 0.002), LOS (p = 0.026), proximal M2 occlusion (p = 0.017), greater infarct volume (p < 0.001), and presence of both cortical and subcortical infarcts (p = 0.039) were predictors of 90-day mortality. ROC curve analyses indicated that an aNIHSS >10 (sensitivity = 0.944, specificity = 0.722, AUC = 0.852, p < 0.001), age >80 years (sensitivity = 0.778, specificity = 0.681, AUC = 0.685, p = 0.015), and infarct volume of >28 ml (sensitivity = 0.833, specificity = 0.806, AUC = 0.877, p < 0.001) best predicted 90-day mortality (online suppl. table 2).

Multivariable analysis showed that an infarct volume >28 ml (OR 11.874, 95% CI 2.630–53.604, p = 0.001) and age >80 years (OR 4.953, 95% CI 1.087–22.563, p = 0.039) were independently associated with 90-day mortality (table 3). In addition, need for intubation (OR 7.788, 95% CI 1.072–56.604) and history of CHF (OR 5.819, 95% CI 1.140–29.695) emerged as unique predictors of 90-day mortality (table 3). When infarct volume, aNIHSS, and age were entered as continuous variables, need for intubation (p = 0.009) and CHF (p = 0.036) remained significantly associated with 90-day mortality (online suppl. table 3).

**Discussion**

In this observational cohort study of stroke patients with M2 occlusions, we found that functional outcomes predominantly fall in two extremes. While most patients will have a good functional outcome by 90 days, the majority of patients with a poor outcome will have died by that time point. The former observation adds to the notion that patients with M2 occlusion have a generally favorable outcome. Prior studies on patients receiving intravenous thrombolysis and/or endovascular therapy showed high recanalization rates and good outcomes in 50–70% of cases [2–4, 12–14]. However, since the majority of studied patients received i.v. recombinant tissue plasminogen activator (rtPA), it is difficult to extrapolate these findings to patients that are ineligible to systemic (or endovascular) recan-
alization strategies. Interestingly, despite the fact that ~75% of patients in our study were not subjected to acute recanalization therapy, the good outcome rates were at the upper limit of previously published ranges [2–4, 12–14]. This observation is important because it might explain why some studies did not note robust functional improvement with i.v. rtPA treatment in patients with distal MCA occlusion [15–17]. The reasons for overall good outcome in untreated patients are likely related to smaller clot burden leading to spontaneous recanalization as well as sparing of lenticulostriate arteries, which together results in smaller infarct volumes [5, 6, 12, 17–22]. Our data supports this hypothesis, as surrogate markers of a large lesion volume such as proximal M2 occlusion and cortical plus subcortical infarction were associated with worse outcome in unadjusted (but not adjusted) analyses. More importantly, consistent with other stroke studies, the absolute lesion volume was the most significant outcome predictor [4–6, 19]. In this respect, it is notable that the herein defined lesion volume cut point best predicting a favorable outcome was ≤26 ml, which is remarkably consistent with previously defined lesion size cutoffs associated with a good outcome [5, 6, 17].

In addition to lesion volume, our data confirms the importance of advanced age as well as higher aNIHSS as critical determinants of outcome [23–25]. Specifically, we found that age ≥80 years was associated with a worse prognosis consistent with generally worse outcome after ischemic stroke in octogenarians.

Recent endovascular therapy-based trials did not show a significant benefit over i.v. thrombolysis with rtPA [26]. In this respect our findings may provide valuable information for a future endovascular trial design as it may help identify and exclude patients that are ‘too good’ (or too poor) to be treated.

Notably, 64% of patients with a poor outcome had died by 90 days. This is in stark contrast to the observed good outcome in >70% of investigated patients. Advanced age, greater infarct volume, history of CHF and need for intubations were independently associated with 90-day mortality. Thus, our study expands on previous observations by confirming these as important risk factors allowing for the identification of a subpopulation of patients with likely very poor outcome after isolated M2 occlusion, and thus aid guiding clinicians in patient management as well as counseling family members.

The strengths of our study relate to the analysis of a large and well-defined patient population with investigation of prospectively collected variables that have been associated with clinical outcome after ischemic stroke as well as masked assessment of data and standardized assessment of 90-day outcome in all patients. Our inclusion of a high number of untreated patients provides important information regarding the natural history of isolated M2 occlusions. Finally, we included volumetric analyses in our predictive models, which is important because infarct volume is increasingly recognized as a key predictor of outcome. The prospective collection of a large number of clinically relevant variables contributed to improved data quality while limiting the potential for misclassification.

Limitations of our study relate to its retrospective design. Further, CTA was obtained at the treating stroke physician’s discretion, which may have biased the selection of patients having worse clinical presentation and outcomes. However, outcome rates were comparable to those published as part of prior studies rendering this possibility less likely [2–4, 12–14]. Given our study design and the limited number of patients that received thrombolytic therapy, the therapeutic efficacy of rtPAs could not be ascertained in this patient population. Lastly, future studies may benefit from assessing the acute lesion volume by defining the Alberta Stroke Program Early Computed Tomography Score (ASPECTS), which has the potential for risk stratification in the hyperacute setting [27, 28].

In conclusion, this study shows generally good outcome after isolated M2 occlusion and confirms the predictive importance of age, aNIHSS, and lesion volume. Additionally, we
provide novel information regarding unique predictors for mortality in this group of patients with otherwise favorable outcome. Such information may aid in risk stratification to help with clinical management as well as to counsel patients and their families.

**Disclosure Statement**

The authors have no conflicts of interest to disclose.

**References**

1. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowsk T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigator; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–774.

2. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, Akhtar N, Orouk FO, Salam A, Shuaib A, Androv AV; CLOTBUST Investigators: Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007;38:948–954.

3. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat O, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelte ST, Anderson C, Spilker J, Carrozzella J, Rycbrost KJ, Janis LS, Martin RH, Foster LD, Tomisk T; Interventional Management of Stroke (IMS) III Investigators: Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368:893–903.

4. Tomisk T, Broderick J, Carrozzella J, Khatri P, Hill M, Palesch Y, Khouy J; Interventional Management of Stroke II Investigators: Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol 2008;29:582–587.

5. Zaidi SF, Aghaebrahim A, Urrha X, Juanta MA, Jankowitz B, Hammer M, Nogueira R, Horowitz M, Reddy V, Jovin TG: Final infarct volume is a stronger predictor of outcome than recanalization in patients with proximal middle cerebral artery occlusion treated with endovascular therapy. Stroke 2012;43:3238–3244.

6. Yoo AJ, Chaudhry ZA, Nogueira RG, Lev MH, Schaefer PW, Schwamm LH, Hirsch JA, Gonzalez RG: Infarct volume is a pivotal biomarker after intra-arterial stroke therapy. Stroke 2012;43:1323–1330.

7. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.

8. Henninger N, Lin E, Baker SP, Wakhloo AK, Takhtani D, Moonis M: Leukoaraiosis predicts poor 90-day outcome after acute large cerebral artery occlusion. Cerebrovasc Dis 2012;33:525–531.

9. Henninger N, Lin E, Haussen DC, Lehamn LL, Takhtani D, Selim M, Moonis M: Leukoaraiosis and sex predict the hyperacute ischemic core volume. Stroke 2013;44:61–67.

10. Gibo H, Carver CC, Rhotan AL Jr, Lenley C, Mitchell RJ: Microsurgical anatomy of the middle cerebral artery. J Neurosurg 1981;54:151–169.

11. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez Tejedor E, Treuillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous tissue plasminogen activator in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245–1251.

12. Legrand L, Nagqara O, Turc G, Mellerio C, Roca P, Calvet D, Labery MA, Baron JC, Mas JL, Meder JF, Touzé E, Oppenheim C: Clot burden score on admission T2*-MRI predicts recanalization in acute stroke. Stroke 2013;44:1878–1884.

13. Shi ZS, Loh Y, Walker G, Duckwiler GR; MERCI and Multi MERCI Investigators: Clinical outcomes in middle cerebral artery trunk occlusions versus secondary division occlusions after mechanical thrombectomy: pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI trials. Stroke 2010;41:953–960.

14. Rahme R, Abruzzo TA, Martin RH, Tomisk T, Ringer AJ, Furlan AJ, Carrozzella J, Khatri P: Is intra-arterial thrombolytic therapy beneficial for M2 occlusions? Subgroup analysis of the PROACT II trial. Stroke 2013;44:240–242.

15. Sandercoc P, Wardlaw JM, Lindley RL, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czolokowska A, Kobayashi A, Ricci S, Murray V, Borge E, Slot KB, Hankey GJ, Correa M, Peeters A, Matz K, Lyer P, Gubitz G, Phillips J, Aran A: The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379:2352–2363.
16. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019–2026.

17. Puetz V, Dzialowski I, Hill MD, Subramaniam S, Sylaja PN, Krol A, O’Reilly C, Hudon ME, Hu WY, Coutts SB, Barber PA, Watson T, Roy J, Demchuk AM; Calgary CTA Study Group: Intracranial thrombus extent predicts clinical outcome, final infarct size and hemorrhagic transformation in ischemic stroke: the clot burden score. Int J Stroke 2008;3:230–236.

18. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH, Yoo AJ, Marshall RS, Meyers PM, Yavagal DR, Wintemark M, Guzy J, Starkman S, Saver JL; MR RESCUE Investigators: A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368:914–923.

19. Rangaraju S, Owada K, Noorian AR, Nogueira RG, Nahab F, Glenn BA, Belagaje SR, Anderson AM, Frankel MR, Gupta R: Comparison of final infarct volumes in patients who received endovascular therapy or intravenous thrombolysis for acute intracranial large-vessel occlusions. JAMA Neurology 2013;70:831–836.

20. Tan YI, Demchuk AM, Hopyan J, Zhang L, Gladstone D, Wong K, Martin M, Symons SP, Fox AJ, Aviv RI: CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. AJNR Am J Neuroradiol 2009;30:525–531.

21. Sillanpaa N, Saarinen JT, Rusanen H, Hakomaki J, Lahtela A, Numminen H, Elovaaara I, Dastidar P, Soimakallio S: The clot burden score, the Boston Acute Stroke Imaging Scale, the cerebral blood volume ASPECTS, and two novel imaging parameters in the prediction of clinical outcome of ischemic stroke patients receiving intravenous thrombolytic therapy. Neuroradiology 2012;54:663–672.

22. Saarinen JT, Sillanpaa N, Rusanen H, Hakomaki J, Huhtala H, Lahtela A, Dastidar P, Soimakallio S, Elovaaara I: The mid-M1 segment of the middle cerebral artery is a cutoff clot location for good outcome in intravenous thrombolysis. Eur J Neurol 2012;19:1121–1127.

23. Saposnik G, Gazik AK, Reeves M, Ovbiagele B, Johnston SC: Stroke prognostication using Age and NIH stroke scale: SPAN-100. Neurology 2013;80:21–28.

24. Saposnik G, Baptis S, Kapral MK, Liu Y, Tu JV, Mamdani M, Austin PC; Investigators of the Registry of the Canadian Stroke Network and the Stroke Outcome Research Canada Working Group: The iScore predicts poor functional outcomes early after hospitalization for an acute ischemic stroke. Stroke 2011;42:3421–3428.

25. Singer OC, Haring HP, Trenkler J, Nohe CH, Bohner G, Reich A, Wiesmann M, Bussmeyer M, Mposaris A, Neumann-Haefelin T, Hohmann C, Niederkorn K, Deutschmann H, Stoll A, Bormann A, Jander S, Turowski B, Brench J, Schlamann M, Petzold GC, Urbach H, Liebeskind DS, Berkefeld J: Age dependency of successful recanalization in anterior circulation stroke: the ENDOSTROKE study. Cerebrovasc Dis 2013;36:437–445.

26. Chimowitz MI: Endovascular treatment for acute ischemic stroke – still unproven. N Engl J Med 2013;368:952–955.

27. Barber PA, Demchuk AM, Zhang J, Buchan AM: Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000;355:1670–1674.

28. Kurre W, Aguilar-Perez M, Niehaus L, Fischer S, Schmid E, Bazner H, Henkes H: Predictors of outcome after mechanical thrombectomy for anterior circulation large vessel occlusion in patients aged ≥80 years. Cerebrovasc Dis 2013;36:430–436.